Raltegravir plus Standard ART in Early HIV Infection

UW PIC 330 Trial
**Study Design: UW 300 PIC**

**Background**: Pilot, open-label, randomized, phase 3 trial evaluating impact of adding raltegravir to standard ART during early HIV.

**Inclusion Criteria (n = 92)**
- Age ≥18 years
- Antiretroviral-naïve
- HIV RNA ≥500 copies/mL <14 days of study entry
- Early HIV infection*

**Treatment Arms**
- RAL 400 mg BID + 2 NRTIs + [NNRTI or PI QD]
- 2 NRTIs + [NNRTI or PI QD]

---

*Early HIV defined as current positive HIV EIA and western blot with either a negative HIV EIA in past 6 months or negative point-of-care test or nonreactive less sensitive HIV EIA in past month

Raltegravir plus Standard ART in Early HIV Infection

UW 330 PIC: Results

First Phase Plasma HIV RNA Decay

HIV RNA decay (log_{10} copies/mL/day)

- Raltegravir + Standard ART: 0.67
- Standard ART: 0.34

**Interpretation:** “Our results suggest homogeneity of responses in cell-associated RNA, HIV DNA, CD4(+) T-cells with replication-competent virus, and 2LTR circles with early HIV in both ART groups. The kinetics of 2LTR DNA did not reflect the kinetics of plasma HIV RNA decline following ART initiation.”
The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.